The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis
- PMID: 32366176
- DOI: 10.1177/1708538120921735
The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis
Abstract
Objectives: Regulatory T cells (Tregs) mediate immunomodulation and protect against atherosclerosis. It is considered that reducing the amount of pro-inflammatory mediators could be achieved by enhancing the anti-inflammatory response, and this may be considered one of the main targets for therapy development. The inhibitory cytokines secreted by Tregs mainly include interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). Based on its known immunosuppressive involvement with other inflammatory disorders, we hypothesized that the newly characterized cytokine interleukin-37 (IL-37) might be associated with the inhibitory functions of Treg in atherosclerosis. Immune regulatory functions of IL-37 have not been completely clarified. Accordingly, we speculated that IL-37 might play a regulatory role in the immunosuppression of Tregs in atherosclerotic disease.
Methods: Real-time polymerase chain reaction and enzyme linked immunosorbent assay were used to test gene expression and protein levels of IL-37 in peripheral blood and localized freshly resected arterial tissues from 84 patients with peripheral arterial occlusive disease and 50 non-atherosclerotic subjects. Results were correlated to disease hallmarks. We also evaluated the ability of recombinant IL-37 to modulate Treg cytokine secretion and T cell inhibition in relation to atherosclerotic disorder in vitro.Results: Our results revealed that IL-37 was increased in patients with chronic lower limb atherosclerotic ischemia, compared to non-atherosclerotic controls. In addition, the expression levels of circulating IL-37 correlated with disease severity of chronic lower limb ischemia. Supplementation with rIL-37 augmented levels of released IL-10 and TGF-β in supernatants of T cells co-cultured with Tregs in the enrolled patients.Conclusions: Results suggest a role for IL-37 in mediating anti-inflammatory functions in the atherosclerotic process, potentially involving enhancement of Treg inhibitory function and anti-inflammatory cytokine secretion with a particularly marked direct response in severe disease.
Keywords: Interleukin-37; Treg cells; interleukin-10; peripheral atherosclerosis; transforming growth factor-beta.
Similar articles
-
Changes and significance of T helper-9 cells and interleukin-9 in patients with atherosclerotic chronic lower limb ischemia: Effect on IL-17 release.Vascular. 2020 Aug;28(4):378-389. doi: 10.1177/1708538120905430. Epub 2020 Feb 16. Vascular. 2020. PMID: 32063130
-
Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells.Sci Rep. 2015 Sep 28;5:14478. doi: 10.1038/srep14478. Sci Rep. 2015. PMID: 26411375 Free PMC article.
-
Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients.Exp Clin Endocrinol Diabetes. 2018 Feb;126(2):96-101. doi: 10.1055/s-0043-113454. Epub 2017 Sep 27. Exp Clin Endocrinol Diabetes. 2018. PMID: 28954308
-
Treg cells in atherosclerosis.Mol Biol Rep. 2021 May;48(5):4897-4910. doi: 10.1007/s11033-021-06483-x. Epub 2021 Jun 12. Mol Biol Rep. 2021. PMID: 34117978 Review.
-
FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.Transpl Immunol. 2012 Jan;26(1):1-10. doi: 10.1016/j.trim.2011.08.009. Epub 2011 Sep 13. Transpl Immunol. 2012. PMID: 21939765 Review.
Cited by
-
Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis.JCI Insight. 2022 Nov 8;7(21):e161244. doi: 10.1172/jci.insight.161244. JCI Insight. 2022. PMID: 36166295 Free PMC article.
-
Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19.Front Cardiovasc Med. 2021 Aug 6;8:630767. doi: 10.3389/fcvm.2021.630767. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34422917 Free PMC article. Review.
-
IL‑37 suppresses macrophage ferroptosis to attenuate diabetic atherosclerosis via the NRF2 pathway.Exp Ther Med. 2023 May 3;25(6):289. doi: 10.3892/etm.2023.11988. eCollection 2023 Jun. Exp Ther Med. 2023. PMID: 37206550 Free PMC article.
-
The Protective Role of Interleukin-37 in Cardiovascular Diseases through Ferroptosis Modulation.Int J Mol Sci. 2024 Sep 10;25(18):9758. doi: 10.3390/ijms25189758. Int J Mol Sci. 2024. PMID: 39337246 Free PMC article. Review.
-
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7.Molecules. 2020 Jun 28;25(13):2968. doi: 10.3390/molecules25132968. Molecules. 2020. PMID: 32605268 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical